Applera, Beckman Finalize Terms of Capillary Electrophoresis Suit
Applera and Beckman Coulter said this week that they have finalized the terms of a patent suit regarding Beckman Coulter's capillary electrophoresis technology and Applera's allegations of breach of contract.
The companies said that the terms of the agreement are "consistent" with those of a preliminary agreement that they disclosed in April (see BioCommerce Week 5/3/2006).
At the time, the companies said that Beckman would grant Applera licenses to its patents for replaceable gels for capillary electrophoresis instruments and DNA sequencers, and to its patent for a heated lid for thermal cyclers. Applera would subsequently pay Beckman $35 million to "release ... any and all claims of infringement relating to DNA sequencer and thermal cycler products."
Under the preliminary terms, Applera also agreed to grant Beckman licenses to its patents for nucleic acid sequencing and real time PCR thermalcycling for use in the diagnostics market. Consequently, Beckman would pay Applera's Celera Genomic segment $20 million over 30 months for rights to use the technology in that market.
Bruker BioSciences Completes Bruker Optics Acquisition
Bruker BioSciences said this week that it closed its acquisition of molecular spectroscopy company Bruker Optics on July 1.
The $135 million purchase price was paid approximately 59 percent in cash and 41 percent in Bruker BioSciences stock. The company said that it issued around 11.4 million new shares for the stock component of the purchase.
The number of shares was determined by dividing the value of the stock consideration, $55.8 million, by $4.91, the trailing average of Bruker closing prices per share for the period of ten consecutive trading days ending three days prior to the closing date.
Bruker BioSciences announced its plan to acquire Bruker Optics in April (see BioCommerce Week 4/19/2006).
The board of directors of Bruker Optics and the independent directors on the board of directors for Bruker BioSciences previously approved the acquisition unanimously.
ABI Licenses Fisher Unit Rights to Provide PCR Products
Applied Biosystems has granted Fisher Biosciences licenses to allow its subsidiary, Abgene, to offer several PCR and real-time PCR products, the companies said last week.
Under the agreement, Abgene will be allowed to offer PCR and real-time PCR reagents and kits, and has the right to develop new real-time PCR products and technologies, the companies said.
Agilent Signs Up Eight New Distributors for Test and Measurement Products
Agilent Technologies selected eight new distributors for its test and measurement products in Europe, the company said last week.
Under the terms of the agreements, these distributors will be the exclusive suppliers for the products in their respective regions.
The company appointed Austria's Elsinger Electronic Handel, France's Francaise d'Instrumentation-Distrame, Germany's Datatec, Switzerland's Distrelec, and the UK's FarnellInOne, a division of Premier Farnell UK. FarnellInOne will also cover all European catalog sales.
For Italy, Agilent selected Gould, Sistemi, and Pansystem. Elfa will cover Sweden, Finland, and Denmark.
The local operators will initially supply customers with Agilent's range of basic power supplies, bench digital multimeters, connectivity solutions, and the 3000 series of oscilloscopes.
GE Healthcare, Spotfire Integrate High-Content Analysis Software
Spotfire and GE Healthcare have integrated their software products into a single product for high-content analysis, the companies said last week.
Specifically, Spotfire's DecisionSite analytics software has been integrated with GE Healthcare's IN Cell Investigator software, which accompanies the IN Cell Analyzer 1000 and 3000 high-content imaging platforms.
GE Healthcare will include a customized version of DecisionSite with IN Cell Investigator "to support the standard quality control and data analysis workflows in cell-based screening," the companies said in a statement.
Financial terms were not disclosed.